Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mural Oncology

4.23
+0.16003.93%
Post-market: 4.20-0.0300-0.71%16:51 EDT
Volume:110.65K
Turnover:452.50K
Market Cap:72.88M
PE:-0.56
High:4.23
Open:4.01
Low:3.77
Close:4.07
Loading ...

This Week's Unlock Schedule: SOLV, APE, and OM to Experience Large One-time Vesting

Blockbeats
·
17 Mar

Mural Oncology Q4 2024 GAAP EPS $(2.01) Misses $(1.96) Estimate

Benzinga
·
12 Mar

Mural Oncology Plc: Cash Runway Extended Into Q1 2026 Through Operational Efficiencies

THOMSON REUTERS
·
12 Mar

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
18 Feb

We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully

Simply Wall St.
·
11 Feb

Promising Prospects for Mural Oncology: Buy Rating Justified by Strong Pipeline and Financial Position

TIPRANKS
·
06 Feb

Mural Oncology Initiated at Buy by Jones Trading

Dow Jones
·
27 Jan

Mural Oncology Advances Drug Pipeline and Extends Runway

TIPRANKS
·
10 Jan

Mural Oncology Achieves Required Overall Survival Events in Trial, Extends Cash Runway

MT Newswires Live
·
10 Jan

Mural Oncology Plc -Company Extends Cash Runway Projection Into Q1 2026 Through Operational Efficiencies

THOMSON REUTERS
·
10 Jan

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

GlobeNewswire
·
10 Jan

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Dec 2024

BRIEF-Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown In Its Artistry-1 Clinical Trial Of Nemvaleukin

Reuters
·
21 Nov 2024

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its Artistry-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for Immunotherapy of Cancer

THOMSON REUTERS
·
21 Nov 2024

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

GlobeNewswire
·
21 Nov 2024

Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Mural Oncology Plc (MURA) and Copa Holdings (CPA)

TIPRANKS
·
14 Nov 2024